FDA: Page
-
MacroGenic moves into phase 1 with new leukemia drug
This first-in-class candidate has a dual mechanism of action.
By Nicole Gray • June 24, 2014 -
Boehringer Ingelheim stops development of hepatitis C drug
The company cites the competitive landscape as the determining factor.
By Nicole Gray • June 24, 2014 -
Companies collaborate to fight multidrug-resistant pathogens
A new diagnostic test is available in Europe and coming to the U.S., but that's just the first step.
By Nicole Gray • June 22, 2014 -
NICE approves Effient for broader use
The product is now acceptable for treatment of many types of acute coronary syndrome.
By Nicole Gray • June 22, 2014 -
Sivextro approved for hard-to-treat skin infections
This is the second drug covered under the FDA's new Qualified Infectious Disease Program designation.
By Nicole Gray • June 22, 2014 -
Deep Dive
Theory can outrun reality on drug approval fast track
The designation can create a buzz that is often not justified.
By Nicole Gray • June 20, 2014 -
FDA seeks to widen warning on testosterone products
The agency wants the products to include a warning about blood clots in veins.
By Randy Lilleston • June 20, 2014 -
J&J rachets up R&D through 12 new alliances
The company has many collaborations underway.
By Nicole Gray • June 20, 2014 -
J&J acquires global rights to influenza drug
If approved, the vaccine would be a new treatment approach to an age-old viral condition.
By Nicole Gray • June 20, 2014 -
Takeda halts development of prostate cancer drug
Phase III trials showed increased progression-free survival, but no significant increases in overall survival.
By Nicole Gray • June 20, 2014 -
PhRMA highlights clinical development of drugs aimed at older Americans
For people over 65, 95% of healthcare spending is for chronic diseases.
By Nicole Gray • June 20, 2014 -
Bellerophon Therapeutics moves PAH treatment into phase II
This add-on therapy could help patients who need additional support despite receiving standard-of-care treatment.
By Nicole Gray • June 20, 2014 -
Pfizer expands immuno-oncology research through Cellectics parnership
Pfizer is expanding oncology research by collaborating with Cellectics, which brings a unique immuno-oncology research platform to the partnership.
By Nicole Gray • June 19, 2014 -
NICE: More novel anticoagulant use could reduce strokes
The British agency has recommended adding novel anticoagulants to formularies throughout the UK.
By Nicole Gray • June 18, 2014 -
Gardasil approved in EU for prevention of anal cancer
The drug now has an expanded therapeutic role in Europe that also includes HPV prevention in adolescents.
By Nicole Gray • June 18, 2014 -
Pfizer, Novartis push for approval of meningitis vaccines
The two companies each have developed a vaccine to prevent a virulent form of meningitis.
By Nicole Gray • June 18, 2014 -
New prescription erectile dysfunction cream introduced to UK
Vitaros (alprostadil cream) is the first cream available for treating erectile function.
By Nicole Gray • June 18, 2014 -
JNJ partners with Viiv to create new combo HIV drug
The medication could end up rivaling Atripla.
By Nicole Gray • June 17, 2014 -
Intarcia presents positive phase III data on a once-yearly diabetes drug
The new therapy may be the key to controlling high blood sugar levels. Intarcia presented positive data at ADA 2014.
By Nicole Gray • June 17, 2014 -
Sanofi, Medtronic team up to offer options for diabetes patients
The new partnership focuses on innovative drug-device breakthroughs.
By Nicole Gray • June 17, 2014 -
Lawsuits target Bayer's Xarelto
There seems to be a growing push in the malpractice community to find harmed patients, although few suits have been filed so far.
By Nicole Gray • June 17, 2014 -
OncoMed halts phase I studies of cancer drugs, but aims to reinitiate
Ths company, which is testing a novel approach to treating cancer at the stem-cell level, is determined to continue development.
By Nicole Gray • June 17, 2014 -
Insulin 300 performs well in phase III trials
Will it beat its competitors?
By Nicole Gray • June 17, 2014 -
Deep Dive
As diabetes soars, so do research and treatment options
Currently, about 180 drugs are in development to address the diabetes-related challenges that persist despite available treatments.
By Nicole Gray • June 16, 2014 -
FDA approves Lymphoseek to help doctors target head, neck cancer locations
The approval marks the latest gain for the diagnostic drug.
By Nicole Gray • June 16, 2014
Previous
